COMBAT: A study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for identification and treatment of GRPr-expressing metastatic castrate-resistant prostate cancer.

Cu-67 SAR-Bombesin - Clarity Pharma

Pluvicto (lutetium Lu 177 vipivotide tetraxetan) - Novartis

https://meetings.asco.org/abstracts-presentations/230443

Luke T. Nordquist; Eva Lengyelova; Frankis Almaguel; Brandon Robert Mancini; Hong Song; Andrew J. Armstrong; Amado J. Zurita; Monique Anderson; Michelle Parker; Robert M. Miller; Andrei Iagaru

Dec 14, 2023